Update on covid vaccine

COVID-19 Vaccine Update (as of December 26, 2025)

Current Recommendations:

1. CDC Guidelines: The CDC's Advisory Committee on Immunization Practices (ACIP) continues to recommend COVID-19 vaccination for everyone who is eligible. Vaccination remains the most effective way to prevent serious outcomes and death from SARS-CoV-2 infection. This includes immunocompromised individuals (CDC, 2023).

1. Updated Vaccines: The FDA has authorized updated COVID-19 vaccines (e.g., Pfizer/BioNTech, Moderna, Novavax) formulated to target currently circulating variants. These vaccines are available in the US and internationally (FDA, 2023).

1. Influenza + COVID-19: The CDC recommends that individuals who have recently recovered from acute COVID-19 should receive the influenza vaccine after isolation (BIII recommendation). Co-administration is possible if necessary (CDC, 2023).

Available Vaccines (2025):

• Pfizer/BioNTech (Comirnaty)

• Moderna (Spikevax)

• Johnson & Johnson (Janssen)

• Novavax (Nuvaxovid)

• AstraZeneca (Vaxzevria) (international)

Key Sources:

• CDC: https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specif (2023)

• FDA: https://www.fda.gov/news-events/press-announcements (2023)

Critical Note: Always check for patient-specific contraindications (e.g., allergies to vaccine components) and consult the latest CDC guidelines before administering vaccines.

Would you like more details on specific vaccine brands or recommendations for special populations?